He added that Cimzia can be a treatment option for patients with Crohn's disease who are refractory to other biological agents as shown in the data.EBSCO_bspPharmaceutical Technology Europe
The article reports on the approval of Tysabri as the new treatment for Crohn's disease. The monoclonal antibody natalizumab which use in treating multiple sclerosis in relapsing form is now approved to treat the moderate-to-severe Crohn's disease of a patient that cannot respond to any ...
More than 65% of refractory Crohn's disease patients treated with infliximab showed a remarkable improvement in their symptoms, which was maintained by repeated infusions every 2 months up to 44 weeks. Patients with draining enterocutaneous fistulae also benefited from infliximab treatment, with more...
Exclusive enteral nutrition (EEN) is a nutritional therapy used for treatment of Crohn’s disease (CD), particularly in children. In practical terms, it requires stopping all usual foods and substituting an exclusive liquid low-residue feed, using either a polymeric or an elemental formula as the...
Recent research and clinical evidence suggest that thalidomide could potentially be used to treat inflammation associated with Crohn's disease. However, systemic side effects associated with large doses of this drug have limited its widespread use. Treatment with thalidomide would prove more efficacious ...
IBD Clinical Trial Information for Gastroenterologists Qu Biologics’ CEO, Dr. Hal Gunn, talks about the research behind QBECO SSI and how this investigational treatment is designed to resolve the underlying trigger for Crohn’s disease and ulcerative colitis....
Progress in the management of Crohn's disease is limited by our inability to compare different patients. Two methods of evaluating the severity of disease have recently been published. Of these, the National Cooperative Crohn's Disease Study (NCCDS) method has been utilized in a study reported ...
Summary Previously, clinicians have had few choices in treating mild to moderate Crohn's disease. They currently treat these Crohn's disease patients with oral mesalamine and antibiotics. This treatment approach is based on the safety of these agents, and the perception that they are effective. Th...
as gut-brain conditions with equal emphasis on the roles of mental and physical health’ [72]. Hopefully, this will result in new randomized controlled trials to evaluate the effectiveness of hypnotherapy as an adjunctive treatment for patients with both ulcerative colitis and Crohn’s disease. ...
The diagnosis, understanding and management of Crohn's disease may have just received a helping hand from a joint ASU Biodesign Institute and Mayo Clinic study aimed at developing a better blood test for the disease.